Improving prostate cancer risk stratification using spatial single-cell tumor profiling. Read more about Improving prostate cancer risk stratification using spatial single-cell tumor profiling.
A phase 1b, open-label, multicenter study of xaluritamig in patients with newly diagnosed localized intermediate- or high-risk prostate cancer in the neoadjuvant setting. Read more about A phase 1b, open-label, multicenter study of xaluritamig in patients with newly diagnosed localized intermediate- or high-risk prostate cancer in the neoadjuvant setting.
Exploring social vulnerability in prostate cancer management: Insights into utilization of watchful waiting and active surveillance from 1998 to 2017. Read more about Exploring social vulnerability in prostate cancer management: Insights into utilization of watchful waiting and active surveillance from 1998 to 2017.
Examining community social vulnerability domains and influence on treatment selection for men with prostate cancer. Read more about Examining community social vulnerability domains and influence on treatment selection for men with prostate cancer.
Evaluating social vulnerability as a key determinant of definitive treatment for Black men with clinically localized prostate cancer. Read more about Evaluating social vulnerability as a key determinant of definitive treatment for Black men with clinically localized prostate cancer.
A phase 1 dose-escalation study of GCC19CART: A novel CAR T-cell therapy for metastatic colorectal cancer in the United States. Read more about A phase 1 dose-escalation study of GCC19CART: A novel CAR T-cell therapy for metastatic colorectal cancer in the United States.
Improving the quality and guideline concordance of multidisciplinary gastric cancer care in a safety net hospital. Read more about Improving the quality and guideline concordance of multidisciplinary gastric cancer care in a safety net hospital.
Implementing a genetic testing station in a safety net setting for equitable genetic testing and counseling. Read more about Implementing a genetic testing station in a safety net setting for equitable genetic testing and counseling.
Being Present-CML: A mindfulness-based intervention for patients with chronic myeloid leukemia taking tyrosine kinase inhibitors. Read more about Being Present-CML: A mindfulness-based intervention for patients with chronic myeloid leukemia taking tyrosine kinase inhibitors.
Therapeutic response and outcomes with uncommon breast cancer subtypes in the I-SPY trial 2010-2022. Read more about Therapeutic response and outcomes with uncommon breast cancer subtypes in the I-SPY trial 2010-2022.
